Liver does not care about age
Because elderly patients have associated diseases, old age has been regarded as an adverse factor for liver resection (LR) [1] . Consequently, resectable hepatic metastasis from colorectal cancer (HMCC) in the elderly are still more frequently treated by chemotherapy. On the other hand, recent series showed that after major LR in aged people, liver function is preserved, with acceptable morbidity [2] . However, the impact on long-term survival is not clear, because aged patients often die of another pathology. Thus, data on 185 patients who had undergone a major LR (removing at least four Couinaud's segments) between January 1990 and December 2002 were retrieved from an ongoing database. Medical charts of patients initially operated on for colorectal cancer were studied by two hepatic surgeons, regardless of name and age. Only patients who fulfilled the further following criteria were selected for the present study: (i) metachronous hepatic metastasis, (ii) needing major LR for up to three metastasis, (iii) no underlying hepatic disease, (iv) no local recurrence of disease, (v) no extra-hepatic metastasis evaluated by repeat body scan, and (vi) no progressive hepatic disease after a treatment-free period of 2 months. Of these, 33 patients were aged at least 70 years old. Fifteen patients underwent direct major LR without postoperative chemotherapy. Eighteen patients received only the LVFU2 regimen combined with irinotecan (FOLFIRI protocol) because of either ASA score 3 (n = 12) or patients refusal of surgery (n = 6). For the two groups, global survival was calculated using the Kaplan -Meier method, and cause of death was examined.
No patient was lost to follow-up or died of a cause other than colorectal cancer disease during a median observation time of 49 months. Mortality and morbidity of group 1 were 0% and 33%, respectively. All patients in group 2 died during the observation time. Survival at 1, 2 and 5 years of all 33 patients were 91%, 61% and 23%, respectively. The median survival rate was 28 months. Survival at 1 and 2 years for groups 1 and 2 were 73% and 50% (P = 0.04) and 47% and 15% (P <0.05), respectively. The median survival for groups 1 and 2 was 22 and 12 months, respectively (P = 0.03).
Our series indicated that exclusive major LR for HMCC in elderly patient can be safe and can improve survival. Patient age is a useful prognostic factor for prediction of postoperative liver failure. Thus, surgeons use less aggressive procedures because of higher comorbidity rates [3] . As a result, we found that postoperative complications and operative mortality rates after major LR did not differ from those in younger patients [4] . Surgical resection of HMCC improved survival because the benefit of major LR was not offset by high postoperative mortality. In fact, patients >70 years old who were eligible for surgery but who are treated exclusively by chemotherapy had a reduced life expectancy. Surgical eligibility is classically determined by number and location of tumors, as for younger patients [5] . In our experience, selected elderly patients with HMCC benefited from resection as much as young patients, and age alone may not be a contraindication to surgery. Association with thermoablation by radiofrequency could raise the limits of management of multimetastatic liver in the elderly. Can bleomycin toxicity in the treatment of testis cancer be batch related?
Bleomycin is an antibiotic complex derived from Streptomyces verticullis culture and excreted by the kidneys. Bleomycin toxicity, predominately skin and pulmonary, has been described since the drug's introduction into testicular cancer management in the 1960s [1] . Previous data from the Royal Marsden have described a 6.8% rate of pulmonary toxicity in an 835-patient series, with increased risk occurring in patients >40 years old, those with impaired glomerular filtration rate (GFR) (<80 ml/min) or with stage IV disease, or if a cumulative dose >300 000 IU was given [2] . No relation to bleomycin batch has been described previously.
At the end of 2003/early 2004, we encountered a number of patients with bleomycin toxicity and decided to investigate whether there was an identifiable cause. We identified 19 patients treated at least in part from the same bleomycin batch (435000 Kyowa). Cumulative bleomycin dose, schedule, prognostic group and bleomycin risk factors were reviewed. Five out of 19 patients (26%) developed grade > _ 3 skin or lung toxicity at total doses of 90 000-300 000 IU, requiring cessation of drug ± corticosteroids. Pulmonary toxicity was observed in three out of 19 (15.8%), a much higher rate than that seen in our previous series [2] . When stratified for stage, GFR, age, prognostic group and chemotherapy schedule, no apparent causal relationship was seen in the patients with toxicity (Table 1) . This association may be due to chance, but given that the only common factor among the group was of the shared bleomycin batch, we are suspicious that this was the causal element.
Batch-related bleomycin toxicity has not to our knowledge been described previously, and we would be interested in hearing the experiences of other physicians using bleomycin doses from this batch. We would encourage establishing a central pharmacy database to enable reporting of all bleomycin toxicity so that batch details may be recorded and patients receiving the drug from a highlighted batch may be identified.
